DBV Technologies to Present Data on VIASKIN® Peanut at AAAAI 2026
DBV Technologies announces that it will present additional data from the phase 3 VITESSE study on the VIASKIN® Peanut patch in children aged 4 to 7 at the 2026 annual meeting of the American Academy of Allergy, Asthma, and Immunology. The company will also host a product forum focused on the potential of epicutaneous immunotherapy (EPIT) in treating food allergies.
DBV Technologies will deliver an oral presentation titled 'VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age' at the 2026 AAAAI annual meeting, which will be held in Philadelphia, Pennsylvania, from February 27 to March 2, 2026. The company will also organize a product forum featuring a panel of allergists to discuss the potential of EPIT to re-educate the immune system in the case of food allergies, examine the impact of early intervention in children allergic to peanuts, and analyze how new therapeutic options enable a more proactive approach to managing this allergy.
Exhibition Details
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
DBV Technologies will be located at booth #1527 in the exhibition hall of the AAAAI, where attendees can receive information about epicutaneous immunotherapy and the VIASKIN® Peanut patch. The advanced-stage biopharmaceutical company focuses on developing treatment options for food allergies and other immune conditions. DBV Technologies is currently studying the use of its proprietary VIASKIN® patch technology to treat food allergies, with ongoing programs in young children aged 1 to 3 years and children aged 4 to 7 years who are allergic to peanuts.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
